RRAS and colorectal carcinoma: Among the 146 DEPs, R-Ras and Transgelin were further validated via immunohistochemistry (IHC) and clinicopathological statistics, and the expression levels of these proteins were found to correlate positively with the survival outcome of Stage III CRC patients.